Ulcerative colitis in adults: A review
Importance Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, with a
prevalence exceeding 400 per 100 000 in North America. Individuals with UC have a lower …
prevalence exceeding 400 per 100 000 in North America. Individuals with UC have a lower …
Newer biologic and small-molecule therapies for inflammatory bowel disease
Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …
bowel disease. This review covers newer treatments that reflect our understanding of the …
Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis
BE Sands, BG Feagan, L Peyrin-Biroulet… - … England Journal of …, 2024 - Mass Medical Soc
Background Tulisokibart is a tumor necrosis factor–like cytokine 1A (TL1A) monoclonal
antibody in development for the treatment of moderately to severely active ulcerative colitis …
antibody in development for the treatment of moderately to severely active ulcerative colitis …
Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists
Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are
chronic, progressive, immune-mediated diseases of adults and children that have no cure …
chronic, progressive, immune-mediated diseases of adults and children that have no cure …
[HTML][HTML] Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease
Background & aims This study compared pharmacokinetics, symptomatic and endoscopic
efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab …
efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab …
Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response
Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …
Tumor necrosis factor inhibitors for inflammatory bowel disease
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Development of Spleen Targeting H2S Donor Loaded Liposome for the Effective Systemic Immunomodulation and Treatment of Inflammatory Bowel Disease
Nanoparticles are primarily taken up by immune cells after systemic administration. Thus,
they are considered an ideal drug delivery vehicle for immunomodulation. Because the …
they are considered an ideal drug delivery vehicle for immunomodulation. Because the …
Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis
Background & Aims Safety is a key consideration when choosing advanced therapies
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …
Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension
MT Abreu, DS Rowbotham, S Danese… - Journal of Crohn's …, 2022 - academic.oup.com
Abstract Background and Aims The UNIFI long-term extension [LTE] study reports the
efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of maintenance …
efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of maintenance …